<DOC>
	<DOCNO>NCT02087241</DOCNO>
	<brief_summary>The aim study combine AZD1775 standard front-line chemotherapy subject advance NSCLC .</brief_summary>
	<brief_title>Ph II Trial Carboplatin Pemetrexed With Without AZD1775 Untreated Lung Cancer</brief_title>
	<detailed_description>This randomise , phase II trial compare AZD1775 plus pemetrexed carboplatin follow maintenance AZD1775 pemetrexed versus pemetrexed carboplatin follow maintenance pemetrexed patient previously untreated metastatic non-squamous NSCLC TP53 mutation . The primary endpoint trial assessment progression-free survival ( PFS ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion Criteria Provision inform consent prior study specific procedure Histologic cytologic diagnosis advance NSCLC , Recurrent Stage IV disease ( accord American Joint Committee Cancer ( AJCC ) stag system , v7.0 ) . No prior chemotherapy locally advance metastatic disease Subjects know EGFR mutation must receive previous treatment EGFR tyrosine kinase inhibitor ; subject know ALK translocation must receive previous treatment ALK inhibitor . No prior radiation therapy whole pelvis ≥25 % total bone marrow area . At least one measurable lesion accord Response Evaluation Criteria Solid Tumours ( RECIST ) v1.1 Mandatory availability tumour tissue ( archival fresh archival available ) TP53 determination . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) score 0 1 . Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥10 g/dL Platelets ≥100,000/μL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , ≤3.0 x upper limit normal ( ULN ) ; 5 x ULN know hepatic metastasis Total bilirubin ≤1.5 x ULN , unless secondary Gilbert 's disease Serum creatinine ≤1.5 x ULN calculate creatinine clearance ( CrCl ) ≥45 mL/min CockcroftGault method Ability swallow oral medication Fertile male subject willing use least one medically acceptable form birth control duration study 2 week treatment stop Female subject childbearing potential fertile female subject childbearing potential agree use adequate contraceptive measure breastfeed , negative serum urine pregnancy test within 72 hour prior start study treatment Predicted life expectancy ≥12 week Must ≥18 year age Willingness ability comply study followup procedure Ability understand nature trial give write informed consent Exclusion criterion Use study drug ≤21 day 5 halflives ( whichever short ) prior first dose AZD1775 Major surgical procedure ≤28 day begin AZD1775 , minor surgical procedure ≤7 day Known central nervous system ( CNS ) disease Subject prescription nonprescription drug product ( i.e . grapefruit juice ) know sensitive CYP3A4 substrates Any known hypersensitivity contraindication component study treatment Any follow cardiac disease currently within last 6 month define New York Heart Association ( [ NYHA ] Appendix G ) ≥ Class 2 Corrected QT interval ( QTc ) &gt; 470 msec ( calculate Fridericia correction formula ) study entry congenital long QT syndrome . Pregnant lactate Any serious , active underlie medical condition would impair ability subject receive study treatment Unable unwilling take folic acid vitamin B12 Presence active cancer , history treatment invasive cancer ≤3 year Psychological , familial , sociological , geographical condition permit compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stage IV Lung Cancer</keyword>
</DOC>